Charles River Laboratories International, Inc. (CRL) fundamentals from SEC filings — revenue $4.0B, net margin -3.6%, diluted EPS $-2.91 in FY2025. Revenue, margins, EPS and free cash flow, year by year.
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $3.5B | $4.0B | $4.1B | $4.0B | $4.0B |
| Net income | $391.0M | $486.2M | $474.6M | $22.2M | -$144.3M |
| Net margin | 11.0% | 12.2% | 11.5% | 0.6% | -3.6% |
| Diluted EPS | $7.60 | $9.48 | $9.22 | $0.20 | $-2.91 |
| Free cash flow | $532.0M | $294.9M | $365.4M | $501.6M | $518.5M |
Figures are as reported to the SEC (EDGAR companyfacts), in the filer's own fiscal years.
Sign in to PortfolioX for the full analysis — ten years of history, segment and geographic breakdowns, valuation multiples, analyst estimates and filings. · PortfolioX home